US Public Offering
Centogene
Kempen & Co is pleased to announce that it acted as Co-Manager to Centogene in its USD 49.0 million Public Offering of Primary and Secondary shares on Nasdaq
Transaction highlights
- Public Offering of Primary and Secondary shares on Nasdaq, raising in total USD 49.0 million through the placement of 3,500,000 common shares at a price per share of USD 14.00, excluding the exercise of the over-allotment option
- The Primary Offering, for which proceeds will go to the Company, raised USD 28.0 million by placing a total of 2,000,000 common shares, and the Secondary Offering, for which proceeds will go to the selling shareholders, raised USD 21.0 million by placing 1,500,000 common shares. The selling shareholders (historical founders, executives and pre-IPO investors) continue to hold a substantial shareholding in the Company
- The transaction represents a sizeable liquidity event for the Company, which completed its USD 56.0 million IPO on Nasdaq in November 2019
- Proceeds from the Primary Offering will be used for R&D to support orphan drug development with Centogene’s knowledge-driven information platform, as well as for working capital and other general corporate purposes
- Kempen & Co was keen to work with Centogene given its unique position in the use of genetic data and artificial intelligence, an emerging focus area for Kempen & Co’s Life Sciences & Healthcare franchise
- In 2020 year to date, Kempen & Co has executed 14 transactions for European Life Sciences companies, including 5 transactions for Nasdaq listed companies
Company description
Centogene is a commercial-stage company focused on rare diseases, transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Centogene aims to bring rationality to treatment decisions and accelerate the development of new orphan drugs by using extensive knowledge of rare diseases, including epidemiological and clinical data, as well as innovative biomarkers. Centogene has developed a global proprietary rare disease platform based on their real-world data repository with c. 3.0 billion weighted data points from over 530,000 patients in more than 120 countries. The platform includes multi-omic data (e.g. epidemiologic, phenotypic, proteomic, metabolomic and genetic data) that reflects a global population, and also a biobank of these patients' blood samples.Relevant Transactions Kempen & Co Life Sciences & Healthcare
Over the past year, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
- Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
- Co-Manager in the USD 600 million US Public Offering by Ascendis Pharma
- Financial advisor in the USD 253 million Immatics’ business combination with Arya Sciences Acquisition Corp.Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
- Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
- Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
- Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
- Co-Manager in the USD 862 million Global Offering by argenx
- Joint Bookrunner in the SEK 1,414 million Capital Increase by Oncopeptides
- Co-Manager in the USD 154 million Global Offering of DBV Therapeutics
- Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical
- Lead Manager in the USD 557 million Global Offering by argenx
- Co-Manager in the USD 79.2 million US Public Offering by Merus
- Co-Manager in the USD 57.5 million Capital Increase by ProQR
- Co-Manager in the USD 150 million Nasdaq IPO of BioNTech
- Sole Bookrunner in the €9.0 million Capital Increase by MDxHealth
- Co-Manager in the USD 20.0 million Global Offering of Celyad
- Co-Manager in the USD 582 million NASDAQ IPO of Genmab
Contact
Read more on:
Transactions
No transactions found
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Initial Public Offering
on Nasdaq
Initial Public Offering
Accelerated Bookbuild Offering
Initial Public Offering on Nasdaq
Initial Public Offering on Nasdaq
Accelerated Bookbuild Offering
Capital increase
Private Placement
US Public Offering
Initial Public Offering
US Public Offering
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Initial Public Offering
Debt financing
US Public Offering
US Public Offering
Green Revolving Credit Facility
Sale to
Combination with
Accelerated Bookbuild Offering
Sale to
Accelerated Bookbuild Offering
Non-listed equity capital raising
Sale of majority stake to
Secondary Sell-Down in Calliditas Therapeutics
Capital increase
Initial Public Offering
Capital Increase
European FinTech
IPO
Accelerated Bookbuild Offering
Private Placement of shares in
Bridge financing
Undisclosed
Initial Public Offering
Rights issue
Accelerated Bookbuild Offering
US Public Offering
Accelerated Bookbuild Offering
US Public Offering
Merger with Arya Sciences Acquisition Corp. and subsequent Nasdaq listing
acquisition of
Initial Public Offering
Private Placement
Private Placement
Accelerated Bookbuild Offering
Global Accelerated Bookbuild Offering
Accelerated bookbuild offering
Sale of 456 unit landmark residential project in prime location The Hague
acquired by
public offer for
Sale and capital increase
and
Sale of Dutch residential development to
Global Offering
Accelerated Bookbuild Offering
Public takeover of
Sale of
to
Accelerated Bookbuild Offering
Capital increase
Global offering
Rights issue
Initial Public Offering on NASDAQ
Secondary placing of Fagron shares
Rights issue
a subsidiary of
Sale of German DIY portfolio to REDOS acting on behalf of Union Investment
Accelerated bookbuild offering
Accelerated Bookbuild Offering on behalf of selling shareholders in
Three-day bookbuild offering
Rights issue
Acquisition of
Initial Public Offering
Accelerated Bookbuild Offering
Block trade in argenx shares
a subsidiary of
Sale of German retail portfolio to a real estate private equity firm
Sale of Dutch residential portfolio managed by
on behalf of investors to
Sale of
to
Bencis Capital Partners
Increase of stake in
Initial Public Offering
Acquisition of
Acquisition of
Acquisition of
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
Block trade in Boskalis shares
US public offering
US public offering
Sale to
US public offering
Sale of Rabo Bouwfonds CIF datacenter portfolio
to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Public offer for
Fundraise
Accelerated bookbuild offering
Public offer by German ADLER Real Estate
for Israeli
Public offer by German Vonovia
Sale of Dynamic Portfolios
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Accelerated bookbuild offering
Sale of 3 German residential portfolios by
to consortium of buyers
Accelerated bookbuild offering
US public offering
Accelerated bookbuild offering
Secondary offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Acquisition by
of
from
Accelerated bookbuild offering
Initial public offering on NASDAQ
Share buy-back program
Acquisition by
of
Accelerated bookbuild offering
Secondary placement of 9.4% stake in
Public offer by
for
Public offer by German Vonovia
For Austrian Conwert
Secondary placement of 15% stake in
Formation of Passoã joint venture with
Accelerated bookbuild offering
Rights issue
Sale of 19% stake in
Accelerated bookbuild offering
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Private placement
Strategic study
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Refinancing
Initial Public Offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco
Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Initial Public Offering
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Rights issue